Buchumschlag

Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab

Aim: To evaluate changes in health-related quality of life (HRQoL) in a Phase II trial (NCT02155647) of treatment-naive patients with metastatic Merkel cell carcinoma treated with avelumab (15-month follow-up). Materials & methods: Mixed-effect Models for Repeated Measures were applied to HRQoL...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Bharmal, Murtuza (VerfasserIn) , Nolte, Sandra (VerfasserIn) , Lebbé, Céleste (VerfasserIn) , Mortier, Laurent (VerfasserIn) , Brohl, Andrew S (VerfasserIn) , Fazio, Nicola (VerfasserIn) , Grob, Jean-Jacquez (VerfasserIn) , Pusceddu, Sara (VerfasserIn) , Hanna, Glenn J (VerfasserIn) , Hassel, Jessica C. (VerfasserIn) , Kiecker, Felix (VerfasserIn) , Ellers-Lenz, Barbara (VerfasserIn) , Bajars, Marcis (VerfasserIn) , Güzel, Gülseren (VerfasserIn) , Nghiem, Paul (VerfasserIn) , Hunger, Matthias (VerfasserIn) , Schlichting, Michael (VerfasserIn) , Henry-Szatkowski, Mickaël (VerfasserIn) , D’Angelo, Sandra P. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2020
In: Future oncology
Year: 2020, Jahrgang: 16, Heft: 27, Pages: 2089-2099
ISSN:1744-8301
DOI:10.2217/fon-2020-0426
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.2217/fon-2020-0426
Verlag, kostenfrei, Volltext: https://www.tandfonline.com/doi/full/10.2217/fon-2020-0426
Volltext
Verfasserangaben:Murtuza Bharmal, Sandra Nolte, Céleste Lebbé, Laurent Mortier, Andrew S Brohl, Nicola Fazio, Jean-Jacquez Grob, Sara Pusceddu, Glenn J Hanna, Jessica C Hassel, Felix Kiecker, Barbara Ellers-Lenz, Marcis Bajars, Gülseren Güzel, Paul Nghiem, Matthias Hunger, Michael Schlichting, Mickaël Henry-Szatkowsk &, Sandra P. D’Angelo
Beschreibung
Zusammenfassung:Aim: To evaluate changes in health-related quality of life (HRQoL) in a Phase II trial (NCT02155647) of treatment-naive patients with metastatic Merkel cell carcinoma treated with avelumab (15-month follow-up). Materials & methods: Mixed-effect Models for Repeated Measures were applied to HRQoL data (FACT-M; EQ-5D-5L) to assess changes over time. Clinically derived progression-free survival was compared with HRQoL deterioration-free survival. Results: Overall, we saw relative stability in HRQoL among 116 included patients, with nonprogression associated with statistically and clinically meaningful better HRQoL compared with progressive disease. Deterioration-free survival rates (49-72% at 6 months, 40-58% at 12 months) were consistently higher/better compared with progression-free survival rates (41/31% at 6/12 months). Conclusion: These findings show unique longitudinal HRQoL data for treatment-naive metastatic Merkel cell carcinoma patients treated with avelumab. Clinical trial registration: NCT02155647 (ClinicalTrials.gov). Infographic: A PDF version of this infographic is available as supplemental material.
Beschreibung:Gesehen am 25.09.2025
Beschreibung:Online Resource
ISSN:1744-8301
DOI:10.2217/fon-2020-0426

Ähnliche Einträge